Literature DB >> 22467319

Urine and serum cathepsin B concentrations in the transitional cell carcinoma of the bladder.

Karel Kotaska1, Pavel Dusek, Richard Prusa, Stepan Vesely, Marek Babjuk.   

Abstract

BACKGROUND: It has been shown that expression and activity of lysosomal proteolytic enzymes (i.e., cathepsin B) correlate with tumor progression in various neoplasms. We investigate possible correlation of cathepsin B concentrations with grading and invasivity of tumorous bladder tissue.
METHOD: Cathepsin B concentrations in serum and urine were measured in 40 patients (29 men, 11 women, mean age 68 years) with transitional cell carcinoma (TCC) of the bladder without metastases and in control group of 64 healthy subjects (28 men, 36 women, mean age 55 years) using commercially available enzymatic immunoassay. Concentration of cathepsin B in urine was adjusted on creatinine. Urinary creatinine in all samples was measured by enzymatic creatinase method. Patients were divided into groups according to the grading (low grading: 18 patients, high grading: 22 patients) and invasivity of the carcinoma (nonmuscle-invasive tumors: 23 patients, invasive tumors: 17 patients). RESULT: Concentrations of cathepsin B in urine were significantly elevated in patients than in control group (Median = 3.87 μg/L vs. 1.35 μg/L, P = 0.0002). Similarly, the ratio of U-cathepsin B/creatinine was significantly higher in patients (Median: 0.44 μg/mmol creatinine vs. 0.17 μg/mmol creatinine, P < 0.0001). U-cathepsin B may prove to be useful biomarker (area under the curve [AUC] = 0.72 and 0.73 for the U-cathepsin B/creatinine ratio, respectively). S-cathepsin B significantly correlated with grading of carcinoma (P = 0.02) and U-cathepsin B and U-cathepsin B/creatinine are positively associated with invasive tumors (P = 0.0001 and P = 0.002).
CONCLUSION: Cathepsin B concentrations correlate well with grading and invasivity of tumors and may have diagnostic value in investigation of bladder cell carcinoma. New index U-cathepsin B/Creatinine ratio is more appropriate biomarker to monitor TCC, than U-cathepsin B so far.
© 2012 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22467319      PMCID: PMC6807346          DOI: 10.1002/jcla.21483

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  20 in total

1.  Upper tract urothelial neoplasms: incidence and survival during the last 2 decades.

Authors:  J J Munoz; L M Ellison
Journal:  J Urol       Date:  2000-11       Impact factor: 7.450

Review 2.  The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee.

Authors:  J I Epstein; M B Amin; V R Reuter; F K Mostofi
Journal:  Am J Surg Pathol       Date:  1998-12       Impact factor: 6.394

3.  Cathepsin B, p53 expression and AgNORs in transitional cell carcinoma.

Authors:  I Akpolat; Y S Bariş; A F Yilmaz; M Bakirtaş; A Saylik; F Karagöz; B Kandemir
Journal:  Neoplasma       Date:  1998       Impact factor: 2.575

Review 4.  Cellular adhesion molecules.

Authors:  H Uchiyama; K C Anderson
Journal:  Transfus Med Rev       Date:  1994-04

5.  Invasive bladder cancer: support for screening.

Authors:  S C Hopkins; K S Ford; M S Soloway
Journal:  J Urol       Date:  1983-07       Impact factor: 7.450

Review 6.  Cathepsin B, Cathepsin H, and cathepsin L.

Authors:  A J Barrett; H Kirschke
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

7.  [A study on cathepsin B-like substance in patients with urological cancer].

Authors:  M Ueda
Journal:  Nihon Hinyokika Gakkai Zasshi       Date:  1993-02

8.  Role of urinary cathepsin B and L in the detection of bladder urothelial cell carcinoma.

Authors:  Robert S Svatek; Jose Karam; Pierre I Karakiewicz; Andrea Gallina; Roberto Casella; Claus G Roehrborn; Shahrokh F Shariat
Journal:  J Urol       Date:  2008-02       Impact factor: 7.450

9.  Carcinoma of the bladder: a clinical and pathological analysis of 87 autopsy cases.

Authors:  K Kishi; T Hirota; K Matsumoto; T Kakizoe; T Murase; J Fujita
Journal:  J Urol       Date:  1981-01       Impact factor: 7.450

10.  The present and future burden of urinary bladder cancer in the world.

Authors:  Martine Ploeg; Katja K H Aben; Lambertus A Kiemeney
Journal:  World J Urol       Date:  2009-02-15       Impact factor: 4.226

View more
  4 in total

1.  Quantitative Detection of Cathepsin B Activity in Neutral pH Buffers Using Gold Microelectrode Arrays: Toward Direct Multiplex Analyses of Extracellular Proteases in Human Serum.

Authors:  Yang Song; Jestin Gage Wright; Morgan J Anderson; Sabari Rajendran; Zhaoyang Ren; Duy H Hua; Jessica E Koehne; M Meyyappan; Jun Li
Journal:  ACS Sens       Date:  2021-09-21       Impact factor: 9.618

2.  Cathepsin D serum and urine concentration in superficial and invasive transitional bladder cancer as determined by surface plasmon resonance imaging.

Authors:  Ewa Gorodkiewicz; Tomasz Guszcz; Wieslawa Roszkowska-Jakimiec; Robert Kozłowski
Journal:  Oncol Lett       Date:  2014-06-12       Impact factor: 2.967

3.  Over-expression of cathepsin B in hepatocellular carcinomas predicts poor prognosis of HCC patients.

Authors:  Jian Ruan; Haiyan Zheng; Xiaodong Rong; Xiaomin Rong; Junyi Zhang; Weijia Fang; Peng Zhao; Rongcheng Luo
Journal:  Mol Cancer       Date:  2016-02-20       Impact factor: 27.401

4.  Quantitative electrochemical detection of cathepsin B activity in breast cancer cell lysates using carbon nanofiber nanoelectrode arrays toward identification of cancer formation.

Authors:  Luxi Z Swisher; Allan M Prior; Medha J Gunaratna; Stephanie Shishido; Foram Madiyar; Thu A Nguyen; Duy H Hua; Jun Li
Journal:  Nanomedicine       Date:  2015-05-08       Impact factor: 5.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.